Rossix.blue.jpg
Home Products About Us Contact
img_8304.jpg

Chromogenic Kits

Learn more about our Chromogenic Kits.

Phospholipid Emulsions

Our highly stable phospholipid emulsions are suitable for use in analyses related to procoagulant and anticoagulant pathways.

References

References

Rossix products are used by well renowned academic scientists as well as by leading pharmaceutical companies.

We perform contract analysis and method development on a regular basis for some of the major global pharmaceutical companies.

For enquiries regarding our track record and/or which types of projects we may handle please contact us directly and we will give you more detailed information.

Scientific publications

The section below presents references in which Rossix products have been utilised as well as publications from Rossix.

Phospholipids

For a reference list on our phospholipids:


Rox Factor IX

Jianming Liu et al

AstraZeneca R&D Mölndal

Protein J. 2014; 33(2): 174-183

Improved Expression of Recombinant Human Factor IX by Co-expression of GGCX, VKOR and Furin.


Rox FIX-A (determination of Factor IXa activity)

Peter L Turecek et al.

Expert Review of Clinical Pharmacology, March 2015, Vol. 8, No. 2 Pages 163 - 177

Nonacog gamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodes.

Gerald Schrenk et al. Baxter Innovations GmbH, Vienna, Austria.

Does the factor IXa content of factor IX products impact function, safety and efficacy.

Poster Presented at the Bari International Conference (8th BIC) 2014 in Bari, Italy, Oct 3-5, 2014

H. V. Wilmot, J.Hogwood and E.Gray

Haemostasis Section, Biotherapeutics Group, National Institute for Biological Standards and Control, Potters Bar, UK

Haemophilia (2014), 20, 891-897

Recombinant factor IX: discrepancies between one-stage clotting and chromogenic assays.

Böhm E, Dockal M, Pilz J, Schrenk G, Varadi K, Scheillinger F.

Superiority of the chromogenic assay specific for activated factor IX (FIXa) over the non-activated partial thromboplastin time (NAPTT) clotting assay in detecting FIXa in recombinant FIX (rFIX) preparations.

XXIV ISTH Congress 2013; Poster PB1.39-6.


Rox Prothrombin

Lövgren A

Recombinant snake venom prothrombin activators.           

Bioengineered  4 (3), 153-157 (2013)

Brenden N, Madeyski-Bengtson K, Martinsson K, Svärd R, Albery-Larsdotter S, Granath B, Lundgren H, Lövgren A

A triple-transgenic immunotolerant mouse model.

J Pharm Sci  102 (3), 1116-1124 (2013).


Other

S. ROSÉN

Chromogenic methods in coagulation diagnostics.

Hämostaseologie Aug;25 (3), 259-266 (2005)

News

2018-06-29 Posters at the SSC meeting in Dublin July 18-21, 2018.

Steffen Rosén and Rossix AB will present two posters at the SSC meeting in Dublin:

PB229 - Overestimation of recombinant wild type FIX potency by a one-stage method indicated from comparison with a chromogenic FXIa and TF/FVIIa based methods and through discrepant activation of rwtFIX and plasma derived FIX by plasma kallikrein.

PB238 - Underassignment of FIX potency of rFIX-Albumin fusion protein by one-stage methods demonstrated in studies on FXIa and FIXa generation. 

  

2016-06-22 Publication in collaboration with NovoNordisk

Rosén P, Rosén S, Ezban M, Persson E.

Overestimation of N-glycoPEGylated factor IX activity in one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX.

J Thromb Haemost 2016; 14: 1420-7.

  

2015-04-13 Publication in collaboration with AstraZeneca

Ann Lövgren et al. Blood Coagulation and Fibrinolysis, Characterization of thrombin derived from 

human recombinant prothrombin.

Open access: click here

  

Search